GlassScriptPhysician profile
Stephen P Lorino
NPI 1649214073
$3,358.43
in general payments reported to CMS, 2019-2025
27 companies · $661 in 2025
The $661 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.06 · 2021: $11.06 · 2022: $708 · 2023: $1,110 · 2024: $855 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,626.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $557.80 | 2022-2025 | |
| Glaxosmithkline, LLC. | $530.54 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $414.34 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $281.81 | 2022-2025 | Gvoke Hypopen |
| Abbvie INC. | $257.18 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.89 | 2022-2025 | Xifaxan |
| Amgen INC. | $136.89 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Genzyme Corporation | $133.18 | 2023 | |
| Lilly USA, LLC | $129.52 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $123.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $96.16 | 2022-2024 | |
| Astellas Pharma US INC | $71.70 | 2024-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $68.80 | 2021-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.49 | 2022-2024 | Ofev |
| Biogen, INC. | $50.00 | 2023 | Vumerity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $49.84 | 2025 | Breztri, Airsupra |
| Exact Sciences Corporation | $44.70 | 2023 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $38.45 | 2024-2025 | Heplisav-B |
| Boston Scientific Corporation | $27.51 | 2025 | Eluvia |
| Cook Medical LLC | $20.63 | 2024 | Zenith |
| Lifescan, INC. | $19.34 | 2022 | |
| Abbott Laboratories | $18.35 | 2025 | Eterna |
| Daiichi Sankyo INC. | $16.26 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.75 | 2023 | |
| Phathom Pharmaceuticals, INC. | $14.18 | 2025 | Voquezna |
| Medtronic Vascular, INC. | $13.06 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lorino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.